ArticleMedical oncology (Northwood, London, England)2025
Lipidomics analysis of ceramidase inhibition-induced intracellular lipid profile changes in lung cancer cells.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is among the most prevalent types of cancer globally and in Türkiye. Basically, lung cancer is divided into 2 different types, of which non-small cell lung cancer (NSCLC) accounts for about 85% of cases. With the elucidation of the mechanism of NSCLC, there is an urgent need to identify effective non-toxic drugs and new target biomarkers. Therefore, an immediate need exists to clarify the mechanism of NSCLC and identify effective, nontoxic drugs and novel target biomarkers. In this study, we aimed to determine intracellular lipid level changes caused by N-Oleoylethanolamine (NOE) and N-Oleoylethanolamine Solid Lipid Nanoparticle (NOESLN) formulations in test cell lines determined by mass spectrometry LC-MS/MS lipidomic analysis. Lipid level changes induced by N-Oleoylethanolamine (NOE) and N-Oleoylethanolamine Solid Lipid Nanoparticle (NOESLN) formulations in test cell lines have been determined by mass spectrometry LC-MS/MS lipidomics analysis. The particle size of the nanoparticle formulation was found to be 100 times smaller compared to the NOE particle size. According to MTT results, IC
Indexed as
Identifiers
41452552What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.